Efficacy of platelet rich plasma injection in treatment of plantar fasciitis

Abstract

<p class="abstract"><strong>Background:</strong> Platelet rich plasma is a recently introduced therapy for treatment of chronic painful conditions in orthopaedics, it acts mainly by promoting healing process. PRP has an increased concentration of platelets which initiate tissue repair by releasing growth factors.<span class="apple-converted-space"> </span>Increased concentrations of autologous platelets yield high concentrations of growth factors, subsequently leading to intensified healing of soft tissue on a cellular level. This study was conducted to evaluate the efficacy of platelet rich plasma injection in treatment of plantar fasciitis<span lang="EN-IN">.</span></p><p class="abstract"><strong>Methods:</strong> This study was conducted on the patients coming to orthopaedic OPD at MGM medical college and hospital, kamothe, Navi Mumbai. Total of 40 planter fasciitis cases were taken in this study. Out these 40 patients 23 were Male and 17 were female. The mean age 45.85 (range 25-75). Patients were followed up for 3 months with regular interval and at each visit vas score was evaluated and noted.Total duration of study was 3 months from October 2016 to December 2016.<strong></strong></p><p class="abstract"><strong>Results:</strong> The mean pre injection vas score was 7.15 (Male – 7.13, Female – 6.70). The mean vas score at time of follow up after one week was 6.20 (Male – 6.22 Female – 6.18). The mean vas score at time of follow up after 6 week was 5.62 (Male – 5.66 Female – 5.70). The mean vas score at time of follow up after 3 months was 3.20 (Male – 3.13 Female – 3.29)<span lang="EN-IN">. </span></p><p class="abstract"><strong>Conclusions:</strong> PRP in plantar fasciitis shows promising short term results providing patients with gradual sustained pain relief, improving daily function and lifestyle activity level. However long term results needs to be evaluated<span lang="EN-IN">.</span></p>

Autologous Blood Injection With Dry-Needling vs Dry-Needling Alone Treatment for Chronic Plantar Fasciitis: A Randomized Controlled Trial

“…2,29 However corticosteroid injections may typically be offered far earlier in a treatment pathway than interventions such as ABI. In addition, many studies have used only a simple 0-10 pain score as an outcome measure, 3,21,27,50 with the only other validated measure used in other studies being the American Orthopaedic Foot & Ankle Society ankle-hindfoot score, 2,29,31 and no studies to date have used any measures of wider or global function.…”

Similar Benefits Seen After Radial Extracorporeal Shockwave Therapy or Autologous Blood Injection in Patients With Chronic Plantar Fasciitis—A Retrospective Cohort Study

“…34,35,54 In addition, the follow-up periods for many studies were often of only short duration, often only 3 months, giving no information as to longer term outcomes. 46,52,55,56 Finally, many studies often use only a simple 0 to 10 pain score as an outcome measure, rather than validated patient-rated outcome measures (PROMs), and with very few studies including any wider measurement of patient global health or function. 38,47,55,57,58…”

“…46,52,55,56 Finally, many studies often use only a simple 0 to 10 pain score as an outcome measure, rather than validated patient-rated outcome measures (PROMs), and with very few studies including any wider measurement of patient global health or function. 38,47,55,57,58…”

“…34,35,54 In addition, the follow-up periods for many studies were often of only short duration, often only 3 months, giving no information as to longer term outcomes. 46,52,55,56 Finally, many studies often use only a simple 0 to 10 pain score as an outcome measure, rather than validated patient-rated outcome measures (PROMs), and with very few studies including any wider measurement of patient global health or function. 38,47,55,57,58 This cohort study compares the outcomes seen in clinical practice for patients treated for plantar fasciitis with either rESWT or ABI, comparing data across a wide range of different outcome measures, with .95% of patients having follow-up data at 6-months postprocedure.…”